- Conditions
- Healthy Aging, Alzheimer Disease
- Interventions
- Lactate infusion
- Other
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 60 Years to 95 Years
- Enrollment
- 24 participants
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 56
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Interventions
- MK-1092, 4.0 nmol/kg, MK-1092, 8.0 nmol/kg, MK-1092, 16 nmol/kg, MK-1092, 32 nmol/kg, MK-1092, 64 nmol/kg, Glargine 3.0 nmol/kg, Lispro 1.2 nmol/kg, Placebo to glargine, Placebo to MK-1092, Dextrose, Insulin
- Drug · Other · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Stroke
- Interventions
- Intranasal Insulin, Intranasal saline
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 40 Years to 89 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Healthy Volunteers
- Interventions
- Acarbose
- Drug
- Lead sponsor
- Oregon State University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 157 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Corvallis, Oregon
- Conditions
- Lysosomal Diseases, Gangliosidosis, GM1
- Interventions
- AAV9-GLB1, Abdominal ultrasound, Rituximab, Sirolimus, Methylprednisolone, Prednisone, Audiology assessment with ABR, Bone density scan (DEXA), Electrocardiogram (EKG), Echocardiogram, Electroencephalogram (EEG) awake and extended overnight, Laboratory tests, Lumbar puncture, Brain MRI/MRS/fMRI, Neurocognitive testing, Neurology exam, PICC or other Central line placement, Skeletal survey, Skin biopsy, Speech and modified barium swallow study, Ophthalmology exam
- Biological · Procedure · Drug + 3 more
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 6 Months to 12 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hypertension
- Interventions
- DEFINITY® infusion, Human Recombinant Regular Insulin infusion, Dextrose infusion, Flow mediated vasodilation, Endothelial cell collection, Microvascular perfusion assessment using Definity, Microneurography
- Drug · Procedure
- Lead sponsor
- Wanpen Vongpatanasin
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Acute Respiratory Distress Syndrome, Critical Illness, Respiratory Failure, Sepsis
- Interventions
- Intravenous Acetaminophen (room temperature), Intravenous Vitamin C (refrigerated), 5% Dextrose (room temperature), 5% Dextrose refrigerated
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 488 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Fresno, California + 34 more
- Conditions
- Type 2 Diabetes
- Interventions
- Exenatide, Glargine, Rapid-acting insulin analogs
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Hypoglycemia; Iatrogenic
- Interventions
- Low Fructose, Saline, Somatostatin, Insulin, Glucagon, Dextrose solution, High Fructose
- Drug
- Lead sponsor
- Jason Winnick
- Other
- Eligibility
- 21 Years to 40 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Type 2 Diabetes
- Interventions
- Lixisenatide (AVE0010), Insulin glulisine QD, Insulin glulisine TID, Insulin Glargine (Mandatory background drug), Metformin (Background drug)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 894 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 46
- States / cities
- Sun City, Arizona • Tempe, Arizona • Little Rock, Arkansas + 41 more
- Conditions
- HRD Cancer, SCLC, Advanced Solid Tumors
- Interventions
- Berzosertib, Sacituzumab Govitecan
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Cystic Fibrosis
- Interventions
- Magnetic resonance relaxometry, Magnetic resonance spectroscopy, Blood Draw, DXA, pQCT
- Diagnostic Test
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 13 Years to 20 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy
- Interventions
- PF-04308515, Prednisone
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Kalamazoo, Michigan
- Conditions
- Diabetes (DM)
- Interventions
- Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min, Dexamethasone, Dextrose 20% solution
- Drug
- Lead sponsor
- David D'Alessio, M.D.
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- West Nile Virus
- Interventions
- Omr-lgG-am, Polygam® S/D, Placebo
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 55 more
- Conditions
- Multiple Myeloma
- Interventions
- belantamab mafodotin, Pembrolizumab
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Indianapolis, Indiana • Charlotte, North Carolina + 1 more
- Conditions
- Peritoneal Mesothelioma, Peritoneal Carcinomatosis, Ovarian Cancer, Gastrointestinal Cancer, Appendiceal Cancer, Atypical Mesothelial Proliferation, Colorectal Cancer
- Interventions
- Sodium Thiosulfate, 5-Fluorouracil, Oxaliplatin, Doxorubicin, Hyperthermic Intraperitonial Chemotherapy, Cisplatin, Mitomycin C
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2034
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Interventions
- MK-5160 16 nmol/kg, MK-5160 32 nmol/kg, MK-5160 64 nmol/kg, Glargine 0.4 U/kg, Placebo to Glargine, Placebo to MK-5160, Dextrose, Glargine 0.6 U/kg
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Tolerability, Healthy, Elderly
- Interventions
- AZD9742, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Springfield, Missouri
- Conditions
- Transgender Persons
- Interventions
- Botnia Clamp, Withdrawal of Gender Affirming Hormone Therapy (GAHT)
- Drug · Other
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Heart Failure, Cardiorenal Disease, Renal Disfunction
- Interventions
- ANX-042, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Type 2 Diabetes
- Interventions
- GIP, Modified GIP, Normal Saline
- Drug
- Lead sponsor
- National Institute on Aging (NIA)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Obesity, Healthy
- Interventions
- PET Scan, Mixed Meal Test, Muscle sympathetic nerve activity (MSNA), Oral Glucose Tolerance Test, Body Composition, Percent Body Fat & Percent Body Water (Tanita scale), CT Scan, Body Composition, Percent Body Fat & Percent Body Water (DXA Scan)
- Diagnostic Test · Dietary Supplement · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Cardiovascular Diseases, Natriuretic Peptides, Cardiometabolic Diseases, Energy Expenditure, Glucose Metabolism, Exercise, Obesity
- Interventions
- Study diet, Exercise capacity VO2 max determination, Exercise Challenge, Glucose Challenge
- Dietary Supplement · Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama